Health

Results: 3733-3744 of 9286

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 2030

Biognosys Launches Spectronaut 20 and SpectroMine 5, Setting New Benchmarks in Immunopeptidomics

PR Newswire associated0

Isotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging

MORE PATIENTS ACROSS ENGLAND AND WALES ARE SET TO BECOME ELIGIBLE FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

PR Newswire associated0

Highlights of ESHG | Rapid AI Karyotype Total Solution From China Makes a Big Splash

The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel compliance and reduce vessel recoil effect.

FDA Grants De Novo Clearance for Reflow Medical's Spur® Peripheral Retrievable Stent System

Dr. Kumar Abhinav (left) and Dr. Mario Teo (right) have to date conducted three cases in the 15 patient clinical trial. The images above show the seamless restoration of cranial flaps using TETRANITE in this clinical trial.

RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive

HistoSonics Non-Invasive Edison Histotripsy System

HistoSonics’ Edison Histotripsy System Gains Great Britain Early Market Access Under Unmet Clinical Needs Authorisation

Sarah Cannon Research Institute to Showcase Cancer Insights at 2025 ASCO® Annual Meeting

Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025